BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 23720055)

  • 1. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma.
    Natsume A; Ito M; Katsushima K; Ohka F; Hatanaka A; Shinjo K; Sato S; Takahashi S; Ishikawa Y; Takeuchi I; Shimogawa H; Uesugi M; Okano H; Kim SU; Wakabayashi T; Issa JP; Sekido Y; Kondo Y
    Cancer Res; 2013 Jul; 73(14):4559-70. PubMed ID: 23720055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis.
    Harutyunyan AS; Krug B; Chen H; Papillon-Cavanagh S; Zeinieh M; De Jay N; Deshmukh S; Chen CCL; Belle J; Mikael LG; Marchione DM; Li R; Nikbakht H; Hu B; Cagnone G; Cheung WA; Mohammadnia A; Bechet D; Faury D; McConechy MK; Pathania M; Jain SU; Ellezam B; Weil AG; Montpetit A; Salomoni P; Pastinen T; Lu C; Lewis PW; Garcia BA; Kleinman CL; Jabado N; Majewski J
    Nat Commun; 2019 Mar; 10(1):1262. PubMed ID: 30890717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
    Orzan F; Pellegatta S; Poliani PL; Pisati F; Caldera V; Menghi F; Kapetis D; Marras C; Schiffer D; Finocchiaro G
    Neuropathol Appl Neurobiol; 2011 Jun; 37(4):381-94. PubMed ID: 20946108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A model for transmission of the H3K27me3 epigenetic mark.
    Hansen KH; Bracken AP; Pasini D; Dietrich N; Gehani SS; Monrad A; Rappsilber J; Lerdrup M; Helin K
    Nat Cell Biol; 2008 Nov; 10(11):1291-300. PubMed ID: 18931660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
    Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
    Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency.
    Shen X; Liu Y; Hsu YJ; Fujiwara Y; Kim J; Mao X; Yuan GC; Orkin SH
    Mol Cell; 2008 Nov; 32(4):491-502. PubMed ID: 19026780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNA HOTAIR promotes glioblastoma cell cycle progression in an EZH2 dependent manner.
    Zhang K; Sun X; Zhou X; Han L; Chen L; Shi Z; Zhang A; Ye M; Wang Q; Liu C; Wei J; Ren Y; Yang J; Zhang J; Pu P; Li M; Kang C
    Oncotarget; 2015 Jan; 6(1):537-46. PubMed ID: 25428914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The JAZF1-SUZ12 fusion protein disrupts PRC2 complexes and impairs chromatin repression during human endometrial stromal tumorogenesis.
    Ma X; Wang J; Wang J; Ma CX; Gao X; Patriub V; Sklar JL
    Oncotarget; 2017 Jan; 8(3):4062-4078. PubMed ID: 27845897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Convergent evolution of chromatin modification by structurally distinct enzymes: comparative enzymology of histone H3 Lys²⁷ methylation by human polycomb repressive complex 2 and vSET.
    Swalm BM; Hallenbeck KK; Majer CR; Jin L; Scott MP; Moyer MP; Copeland RA; Wigle TJ
    Biochem J; 2013 Jul; 453(2):241-7. PubMed ID: 23679895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRC2 activates interferon-stimulated genes indirectly by repressing miRNAs in glioblastoma.
    Shivram H; Le SV; Iyer VR
    PLoS One; 2019; 14(9):e0222435. PubMed ID: 31513636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An H3K36 methylation-engaging Tudor motif of polycomb-like proteins mediates PRC2 complex targeting.
    Cai L; Rothbart SB; Lu R; Xu B; Chen WY; Tripathy A; Rockowitz S; Zheng D; Patel DJ; Allis CD; Strahl BD; Song J; Wang GG
    Mol Cell; 2013 Feb; 49(3):571-82. PubMed ID: 23273982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct Stimulatory Mechanisms Regulate the Catalytic Activity of Polycomb Repressive Complex 2.
    Lee CH; Holder M; Grau D; Saldaña-Meyer R; Yu JR; Ganai RA; Zhang J; Wang M; LeRoy G; Dobenecker MW; Reinberg D; Armache KJ
    Mol Cell; 2018 May; 70(3):435-448.e5. PubMed ID: 29681498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycomb Repressive Complex 2 Methylates Elongin A to Regulate Transcription.
    Ardehali MB; Anselmo A; Cochrane JC; Kundu S; Sadreyev RI; Kingston RE
    Mol Cell; 2017 Dec; 68(5):872-884.e6. PubMed ID: 29153392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Jarid2 Methylation via the PRC2 Complex Regulates H3K27me3 Deposition during Cell Differentiation.
    Sanulli S; Justin N; Teissandier A; Ancelin K; Portoso M; Caron M; Michaud A; Lombard B; da Rocha ST; Offer J; Loew D; Servant N; Wassef M; Burlina F; Gamblin SJ; Heard E; Margueron R
    Mol Cell; 2015 Mar; 57(5):769-783. PubMed ID: 25620564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2 is essential for glioblastoma cancer stem cell maintenance.
    Suvà ML; Riggi N; Janiszewska M; Radovanovic I; Provero P; Stehle JC; Baumer K; Le Bitoux MA; Marino D; Cironi L; Marquez VE; Clément V; Stamenkovic I
    Cancer Res; 2009 Dec; 69(24):9211-8. PubMed ID: 19934320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation.
    Caretti G; Di Padova M; Micales B; Lyons GE; Sartorelli V
    Genes Dev; 2004 Nov; 18(21):2627-38. PubMed ID: 15520282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
    Xu B; Konze KD; Jin J; Wang GG
    Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
    Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
    Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Dimeric Structural Scaffold for PRC2-PCL Targeting to CpG Island Chromatin.
    Chen S; Jiao L; Liu X; Yang X; Liu X
    Mol Cell; 2020 Mar; 77(6):1265-1278.e7. PubMed ID: 31959557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.